Overview

Sevelamer, Fetuin-A and Endothelial Dysfunction in CKD

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
Vascular calcification and endothelial dysfunction (ED) contribute to the development of cardiovascular disease (CVD) in patients with chronic kidney disease (CKD). Sevelamer, a non-calcium based phosphate binder, has been shown to attenuate cardiovascular calcification in CKD patients while the exact mechanism has not been clarified. This study was designed to investigate the effect of short-term sevelamer treatment on both serum fetuin-A concentrations and ED seen in CKD patients.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Gulhane School of Medicine
Treatments:
Calcium
Calcium acetate
Sevelamer
Criteria
Inclusion Criteria:

- CKD stage 4 patients

- Older than 18 years of age

- Non-diabetic

- Serum phosphorus > 5.5 mg/dl

Exclusion Criteria:

- Diabetes mellitus

- History of coronary artery disease

- Smokers

- Taking statins or renin-angiotensin blockers